COMP <GO>
NGVT vs IOSP // EV/EBITDA & P/E VALUATION
Ingevity Corporation (NYSE) VS. Innospec Inc. (NASDAQ) • 15-METRIC TALLY: NGVT 9
— IOSP 2
▲ EV/EBITDA & P/E VALUATION LEADER: NGVT
LAST: $75.37 (+1.62%) • MKT CAP: $2.59B
valuation
6.0x
LAST: $101.41 (+0.71%) • MKT CAP: $2.50B
valuation
17.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NGVT VS. IOSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NGVT | IOSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 39.50% | 27.70% | +11.80 | NGVT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 9.90% | +75.10 | NGVT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.0x | 17.0x | -11.00 | NGVT | /valuation <GO> |
| Free Cash Flow Yield | 12.78% | 5.54% | +7.24 | NGVT | /fcf-yield <GO> |
| Operating Margin | 35.90% | 7.30% | +28.60 | NGVT | /operating-margins <GO> |
| Net Profit Margin | -14.30% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -2.70% | -3.70% | +1.00 | NGVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.70% | -1.70 | IOSP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.93 | 5.47 | -2.54 | IOSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 4/9 | +2.00 | NGVT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.0 | 59.5 | +2.48 | NGVT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.59B | $2.50B | $93.2M | NGVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NGVT REV | IOSP REV | NGVT GROSS % | IOSP GROSS % | NGVT FCF | IOSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.17B | $1.78B | 39.5% | 27.7% | $331.2M | $138.3M |
| FY 2024 | $1.20B | $1.85B | 38.7% | 29.4% | $128.6M | $184.5M |
| FY 2023 | $1.22B | $1.95B | — | — | $205.1M | $207.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NGVT // BETA —
IOSP // BETA —